Clinical Trial Design
This session focuses on the basics required for study design and outcome measures.
This session focuses on the basics required for study design and outcome measures.
This session consists of highly ranked abstracts that were not accepted for a late-breaking abstract presentation. However, their research is important. The topics include DRG, SCS, and non-invasive forms of stimulation.
Advanced Practice Providers are an integral part of neuromodulation practices around the world, and their role needs to be supported through education in their field, training on the application of their skill sets, and gaining insight on how to provide well-rounded care. Specifically, this session will provide tools to improve their practice in a multidisciplinary field.
Brittney Misercola, APRN FNP-C CFRN LP
Teresita Devera, MSN CRNP ANP-BC
Beth Parente, PA-C
Ashley Comer, MSN APRN FNP-C
Electroconvulsive therapy (ECT) is a long-standing treatment modality with demonstrated efficacy in addressing severe psychiatric illnesses, including major depressive disorder, bipolar disorder, schizophrenia, and psychotic depression. Unlike antidepressant medications, ECT is characterized by an acute time course of response, though benefits can deteriorate over time and carry a significant side effect profile, including memory impairment. This session will review the state-of-the-art in terms of electroconvulsive therapy for psychiatric disease and explore emerging research.
Ketamine has recently attained FDA approval for the treatment of major depressive disorder that is refractory to other therapies. Unlike other medical antidepressant interventions, its effects are immediate and are being integrated into the therapeutic approach to acutely suicidal and destabilized patients. However, serious limitations to its therapeutic potential exist in the transient temporal profile of response, as well as in the potential for abuse. This session will also explore the role of Ketamine in the treatment of refractory psychiatric illness and the mechanistic implications of Ketamine therapy on our understanding of disease pathophysiology.
Amber M Leaver, PhD
Gregory Sahlem, MD
Asim A Shah, MD
Patricio Riva Posse, MD